Harvard School of Public Health (HSPH)

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Approved3

Phase 31

By Therapeutic Area

top 2

Infectious Disease

350%

Immunology

117%

R&D Momentum

41/100

Pipeline Velocity

11/100

Trial Completion Rate

82/100

Pipeline Concentration

39/100

Pipeline Freshness

64/100

Strategic Signals

↗Mature portfolio may be looking to in-license early assets
↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Active, not recruiting

Point-of-Care HIV Testing and Early Dolutegravir Use for Infants

Jul 8, 2026

Active, not recruiting

Targeting Strategies of Antenatal Balanced Energy and Protein Supplementation in Addis Ababa, Ethiopia

Jul 7, 2026

Enrolling by invitation

Community Gateway to Health Study

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

KaletraApproved

ViramuneApproved

ViramuneApproved

ViramunePhase 3

ViramuneApproved

ViramuneApproved

Unknown / Other

Adverse Effect

KaletraApproved

AIDS

ViramuneApproved

Chorioamnionitis

ViramunePhase 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)